Keefe Anthony D, Schaub Robert G
Archemix Corporation, 300 Third Street, Cambridge, MA 02142, USA.
Curr Opin Pharmacol. 2008 Apr;8(2):147-52. doi: 10.1016/j.coph.2007.12.005. Epub 2008 Jan 28.
The first therapeutic aptamer was approved for human use in 2004, and a range of chemical substitutions that improve the drug-like properties of aptamers has recently been shown to increase the utility of this modality. Currently there are both anticoagulant and antithrombotic aptamers in the clinic, and additionally there are a number of earlier stage projects in which a variety of cardiovascular targets are inhibited by specific aptamers and for which a wide range of therapeutic applications has been suggested.
首个治疗性适配体于2004年获批用于人体，最近已证明一系列改善适配体类药物性质的化学取代可提高这种治疗方式的效用。目前临床上既有抗凝适配体也有抗血栓适配体，此外还有一些早期项目，其中特定适配体可抑制多种心血管靶点，并已提出了广泛的治疗应用。
